

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/073603 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 103/00 (2006.01)

A61P 35/00 (2006.01) A61K 103/30 (2006.01)

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2022/060331

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

27 October 2022 (27.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/272,447 27 October 2021 (27.10.2021) US

(71) Applicants: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH). **ADVANCED ACCELERATOR AP-
PLICATIONS** [FR/FR]; 20 Rue Diesel, 01630 Saint-Ge-
nis-Pouilly (FR).

(72) Inventors: **AIMONE, Paola Daniela**; Novartis Phar-
ma AG, Postfach, 4002 Basel (CH). **CHICCO, Daniela**;
Advanced Accelerator Applications (Italy) S.R.L., Via
dell'industria Prima Traversa, 86077 Pozzilli (Isernia) (IT).
MARIANI, Maurizio F.; Advanced Accelerator Applica-
tions (Italy) S.R.L., Via dell'industria Prima Traversa, 86077
Pozzilli (Isernia) (IT). **ZOR, Evren**; Novartis Pharma AG,
Postfach, 4002 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse
35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: COMBINATION THERAPY OF RADIONUCLIDE COMPLEX

(57) Abstract: The present disclosure is directed to a method of treating glioblastoma in a subject in need thereof comprising admin-
istering to said subject an efficient amount of a radiopharmaceutical compound. The present disclosure is also directed to methods of
treating glioblastoma in a subject in need thereof comprising administering to said subject an efficient amount of a radiopharmaceutical
compound in combination with a step of irradiating the subject with an efficient dose of ionizing radiations, and optionally, with a
therapeutically efficient amount of an alkylating agent, preferably temozolomide.

